Pfizer Inc. (PFE)
| Previous close | 37.17 |
| Open | 37.26 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 3200 |
| Day's range | 37.26 - 37.74 |
| 52-week range | 29.99 - 43.08 |
| Volume | 24,613,013 |
| Avg. volume | 31,692,008 |
| Market cap | 209.739B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | 22.03 |
| EPS (TTM) | 1.71 |
| Earnings date | 04 May 2021 |
| Forward dividend & yield | 1.56 (4.20%) |
| Ex-dividend date | 28 Jan 2021 |
| 1y target est | 40.64 |
- Editor's pickYahoo Finance
Coronavirus update: J&J vaccine pause remains, Oxford studies blood clots and COVID-19 vaccines
Blood clot concerns lack context, experts say, putting pressure on federal agencies to unpause J&J vaccinations.
- Business Wire
Pfizer Invites Shareholders to Attend Virtual-Only 2021 Annual Meeting of Shareholders on April 22
Pfizer Inc. (NYSE: PFE) announced today that shareholders and the general public are invited to access its virtual-only 2021 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 22, 2021. As previously disclosed, this year’s meeting will be held virtually due to continued public health concerns related to the COVID-19 pandemic and to support the health and well-being of our shareholders and other meeting participants. We have designed the virtual Annual Meeting to ensure that our shareholders who attend the virtual Annual Meeting will be afforded comparable rights and opportunities to participate as they would at an in-person meeting.
- Zacks
Bristol Myers' (BMY) Opdivo Combo Gets EU Nod for First-Line RCC
The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Cabometyx for first-line treatment of advanced renal cell carcinoma.
